Georgia's Online Cancer Information Center

Multiple Myeloma Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Multiple Myeloma
Cancer Type = Multiple Myeloma
There are currently 40 active Multiple Myeloma clinical trials in Georgia.
1.
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT05675449
Protocol IDs
C1071020
NCI-2023-01590
MAGNETISMM-20
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
2.
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT05201781
Protocol IDs
CR109123
NCI-2022-01309
2020-005521-84
2023-505530-10-00
68284528MMY4002
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
3.
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT04910568
Protocol IDs
GO42552
NCI-2021-07543
2021-000238-33
4.
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT05651932
Protocol IDs
KTX-MMSET-001
NCI-2023-01697
EUCTR No: 2022-500801-41-00
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
5.
A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT03215030
Protocol IDs
TAK-573-1501
NCI-2017-01894
U1111-1195-8134
TV48573-ONC-10128
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
6.
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Cancer Type
Hematopoietic Malignancies, Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT05050097
Protocol IDs
CR108946
NCI-2021-13605
2020-004502-55
64407564MMY1004
8.
9.
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT03601078
Protocol IDs
BB2121-MM-002
NCI-2018-01730
U1111-1216-4209
2018-000264-28
Treatment Sites (1)
10.
Battery Powered Drill versus Conventional Methods in Comparing Quality of Bone Marrow Biopsy, Convenience, and Pain Control in Patients with Plasma Cell Disorders
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT03078452
Protocol IDs
Winship2656-14
NCI-2017-00308
IRB00075658
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
11.
BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT04318327
Protocol IDs
CADPT07A12101
NCI-2020-06513
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
12.
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT05208307
Protocol IDs
Winship5382-21
NCI-2021-08385
STUDY00003092
13.
NCORP Trial
Biospecimen Collection in Identifying Genetic Changes in Patients with Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Kidney Cancer, Liver Cancer / Hepatoblastoma, Multiple Myeloma, Plasma cell neoplasm, Prostate Cancer , Solid Tumor, Unknown Primary
NCT ID
NCT04955808
Protocol IDs
DCP-002
DCP-002
DCP-002
NCI-2017-01572
Treatment Sites (1)
14.
Chaplain-Delivered Compassion Meditation to Improve Quality of Life in Patients Receiving a Stem Cell Transplant
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT05274763
Protocol IDs
EU5492-21
NCI-2022-00233
STUDY00003563
15.
Collection and Storage of Tissue and Blood Samples from Patients with Cancer
Cancer Type
Lymphoma, Multiple Myeloma, Plasma cell neoplasm, Solid Tumor
NCT ID
NCT02474160
Protocol IDs
9846
9846
NCI-2015-00863
P9846
P9846_R02PAPPHOLD01
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
16.
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma with Kidney Failure
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT04352205
Protocol IDs
WINSHIP4949-20
NCI-2020-01133
NCI-2020-01133
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
17.
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT03399799
Protocol IDs
CR108404
NCI-2018-00367
64407564MMY1001
2017-002400-26
18.
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT03145181
Protocol IDs
CR108206
NCI-2017-01157
64007957MMY1001
2016-002122-36
19.
GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies
Cancer Type
Hematopoietic Malignancies, Leukemia, Multiple Myeloma
NCT ID
NCT04824794
Protocol IDs
GCT3014-01
NCI-2021-05589
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
20.
Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT04776395
Protocol IDs
WINSHIP5157-20
NCI-2020-08351
21.
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients with Multiple Myeloma
Cancer Type
Bone Tumor, Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT03858205
Protocol IDs
16M-18-2
NCI-2018-03600
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
22.
Melphalan before Stem Cell Transplant for the Treatment of Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT04483206
Protocol IDs
WINSHIP5001-20
NCI-2020-04920
STUDY00000449
23.
Myeloma-Developing Regimens Using Genomics (MyDRUG)
Cancer Type
Multiple Myeloma
NCT ID
NCT03732703
Protocol IDs
MyDRUG (MMRC-085)
NCI-2019-00698
Treatment Sites (1)
24.
NCORP Trial
National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type
Leukemia, Lung Cancer, Multiple Myeloma, Plasma cell neoplasm, Prostate Cancer , Solid Tumor
NCT ID
NCT04314401
Protocol IDs
10323
10323
NCI-2020-00750
Treatment Sites (18)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
25.
Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT05204160
Protocol IDs
Winship5388-21
NCI-2021-08718
STUDY00003182
26.
PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT05172596
Protocol IDs
CPHE885B12201
NCI-2022-04181
2021-003747-22
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
28.
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
Cancer Type
Multiple Myeloma
NCT ID
NCT01838512
Protocol IDs
CA204-008
Treatment Sites (2)
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
29.
Rifaximin in Treating Patients with Monoclonal Gammopathy
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT03820817
Protocol IDs
Winship4480-18
NCI-2018-02106
IRB00106380
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
30.
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
Cancer Type
Leukemia, Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT03486067
Protocol IDs
CC-93269-MM-001
NCI-2018-02280
2017-003448-19
U1111-1210-6325
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
31.
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia
Cancer Type
Leukemia, Multiple Myeloma
NCT ID
NCT02952508
Protocol IDs
DCL-16-001
NCI-2017-01758
32.
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
Cancer Type
Multiple Myeloma
NCT ID
NCT02899052
Protocol IDs
M15-538
NCI-2016-01672
Treatment Sites (1)
33.
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT04879043
Protocol IDs
HDP-101-01
NCI-2021-04304
34.
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Cancer Type
Multiple Myeloma, Non-Hodgkin Lymphoma
NCT ID
NCT04756726
Protocol IDs
CFT7455-1101
NCI-2021-05587
35.
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT05317416
Protocol IDs
C1071007
NCI-2023-06350
2021-006052-14
MagnetisMM-7
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
36.
NCORP Trial
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type
Multiple Myeloma, Non-Hodgkin Lymphoma, Plasma cell neoplasm
NCT ID
NCT02693535
Protocol IDs
Pro00014171
NCI-2017-00510
Treatment Sites (3)
37.
38.
39.
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Plasma cell neoplasm
NCT ID
NCT03805789
Protocol IDs
CSL964_2001
NCI-2019-03310
2018-000329-29
Treatment Sites (1)
40.
Venetoclax and Tocilizumab for the treatment of Patients with Relapsed or Refractory t(11;14) Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT05391750
Protocol IDs
WINSHIP5273-21
NCI-2021-02510
STUDY00002448
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.